US FDA approves Jazz Pharma's drug for rare brain tumor
06/08/2025 19:39
Corrects spelling in paragraph 1 Aug 6 (Reuters) - The U.S. Food and Drug Administration said on Wednesday that it has approved Jazz Pharmaceuticals' JAZZ.O drug to treat diffuse midline glioma, a rare and aggressive tumor, in adults and children aged one year and older. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Tasim Zahid) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032